According to the Congressional Budget Office (CBO), enacting the bill would increase direct spending by about $18.7 billion and increase direct revenues by $26.2 billion, resulting in a net decrease in the deficit of $7.6 billion by 2029.
The Congressional Budget Office (CBO) has released its score of the Senate Committee on Health, Education, Labor, and Pensions’ proposed bill, S.1895, the Lower Health Care Costs Act. According to the CBO, enacting the bill would increase direct spending by about $18.7 billion and increase direct revenues by $26.2 billion, resulting in a net decrease in the deficit of $7.6 billion by 2029.
The proposed legislation comprises 5 elements: ending surprise medical bills, reducing the prices of prescription drugs, improving transparency in health care, improving public health, and improving the exchange of health information.
Among those sections, elements aimed at reducing drug prices would be responsible for a substantial share of the savings; the CBO says that these provisions would result in a net decrease in the deficit of $4.6 billion over the coming decade.
Key to reducing drug prices are several of the bill’s provisions that apply to generics and biosimilars. According to the CBO, some of these elements of the bill would allow generics and biosimilars to reach the market sooner, leading to a decline in federal spending on prescription drugs and subsidies for health insurance.
Provisions in this portion of the bill would allow the FDA to:
The CBO states that the section of the bill providing the right to sue over sample availability and removal of the requirement to share a risk management system would, on its own, account for more than $3.7 billion in savings over 10 years. This substantial reduction in the deficit would result, in part, from the ability of generics and biosimilars to reach the market 1 to 2 years earlier, on average.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.